Metrics to compare | 688222 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688222PeersSector | |
|---|---|---|---|---|
P/E Ratio | 90.2x | 34.5x | −0.4x | |
PEG Ratio | 1.22 | 0.31 | 0.00 | |
Price/Book | 7.2x | 2.9x | 2.6x | |
Price / LTM Sales | 19.1x | 4.6x | 3.0x | |
Upside (Analyst Target) | 14.4% | 33.7% | 57.2% | |
Fair Value Upside | Unlock | 27.1% | 9.6% | Unlock |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.